Drug Discovery

Twist Bioscience announces strategic collaboration with Schrödinger for drug discovery

Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a collaboration with Schrödinger, a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.

Astellas, Adaptimmune sign deal to co-develop T-cell therapies for cancer

Astellas Pharma has signed a deal worth up to $897.5m with Adaptimmune Therapeutics to co-develop and co-commercialise stem-cell derived allogeneic CAR-T and TCR T-cell therapies for cancer.

BioMotiv and Atomwise sign AI partnership to transform therapeutic development

BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies.

Charles River, Takeda announce scientific collaboration to identify and develop preclinical candidates

Charles River announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company.

NeuroBo Pharmaceuticals and Gemphire Therapeutics complete merger

NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals and Gemphire Therapeutics closed on December 31, 2019.

Eli Lilly to buy biopharmaceutical firm Dermira for $1.1bn

Eli Lilly has agreed to acquire US-based biopharmaceutical company Dermira in an all-cash transaction valued at around $1.1bn.

Gilead Sciences licences portfolio of HIV antibodies from The Rockefeller University

Gilead Sciences announced that the company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.

GHO Capital acquires CDMO Ardena

Global Healthcare Opportunities, or GHO Capital Partners LLP, the European specialist investor in healthcare, together with the existing management team has acquired Ardena, a specialist contract development and manufacturing organization (CDMO) focused on early phase drug development, from Mentha Capital.

Empirico, Ionis collaborate to develop antisense oligonucleotide therapeutics

Empirico has entered into a $660m deal with Ionis Pharmaceuticals to develop novel antisense oligonucleotide therapeutics.